HK:2186 Stock Latest News
Company AnnouncementsLuye Pharma Delivers Higher H1 Profit Despite Revenue Decline2M ago
Company AnnouncementsLuye Pharma Advances HPV mRNA Vaccine LY01620 to Phase II in China2M ago
Company AnnouncementsLuye Pharma Sets Board Meeting to Approve Interim Results and Consider Dividend2M ago- Company AnnouncementsLuye Pharma Advances CNS Portfolio With Successful U.S. Bridging Trial for LY030152M ago
Company AnnouncementsLuye Pharma Wins Shareholder Backing for All AGM Resolutions and Capital Mandates4M ago
Company AnnouncementsLuye Pharma’s Novel CNS Drug LY03015 Delivers Strong Phase 2 Data in Tardive Dyskinesia4M agoCompany AnnouncementsLuye Pharma Halves 2028 Convertible Bond Float With US$89.74 Million Buyback4M ago
Company AnnouncementsLuye Pharma Raises US$180 Million via Premium-Priced 2031 Convertible Bonds4M ago
Company AnnouncementsLuye Pharma Wins Vienna MTF Listing Approval for New Bond Issue4M ago
Company AnnouncementsLuye Pharma to Swap 2028 Convertible Debt with New 2031 Issue5M ago
Company AnnouncementsLuye Pharma Plans Bond Buyback and New USD Convertible Issue5M ago
Company AnnouncementsLuye Pharma sets 2026 AGM to renew board, auditor and share issuance mandate5M ago
Company AnnouncementsLuye Pharma Starts U.S. PK Bridging Trial for Novel CNS Drug LY030156M agoCompany AnnouncementsLuye Pharma Advances Alzheimer’s Psychosis Drug LY03017 Into China Phase II Trial6M ago
Company AnnouncementsLuye Pharma Starts Phase II Trial in China for Next-Generation Schizophrenia Drug LY030206M ago
Company AnnouncementsLuye Pharma Delivers Double-Digit Profit Growth in 2025 but Skips Dividend7M ago- Company AnnouncementsLuye Pharma Sets March 2026 Board Meeting to Approve 2025 Results7M ago
Company AnnouncementsLuye Pharma Completes RMB1.09 Billion Transfer of 25% Stake in Nanjing Luye to NJ Xinshi9M ago
Company AnnouncementsLuye Pharma Injects RMB285 Million into Nanjing Unit via Structured Deal9M ago
Company AnnouncementsLuye Pharma’s Ruoxinlin NDA for Anxiety Disorder Accepted in China, Targeting Major CNS Market Gap9M ago